SLC5A2 and cancer: Although the mortality analysis included a broad population of cancer patients, resulting in high heterogeneity (I2 = 98%), the significant risk reduction and consistent findings in the subgroup and sensitivity analyses strongly support the hypothesis that SGLT2 inhibitors may improve outcomes in cancer patients.